WA
TEVA icon

Waverly Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Waverly Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$358K Buy
11,896
+212
+2% +$6.82K ﹤0.01% 1224
2025
Q4 		$365K Buy
11,684
+1,072
+10% +$26.4K ﹤0.01% 1130
2025
Q3 		$214K Buy
10,612
+60
+0.6% +$1.05K ﹤0.01% 1190
2025
Q2 		$177K Buy
+10,552
New +$170K ﹤0.01% 1137
2018
Q1 		– Sell
-180
Closed -$3K – 344
2017
Q4 		$3K Buy
+180
New +$2.71K ﹤0.01% 380
2015
Q4 		– Sell
-583
Closed -$33K – 363
2015
Q3 		$33K Buy
+583
New +$37.8K 0.02% 190
2014
Q4 		– Sell
-352
Closed -$19K – 649
2014
Q3 		$19K Sell
352
-115
-25% -$6.09K 0.01% 351
2014
Q2 		$24K Buy
467
+106
+29% +$5.42K 0.01% 305
2014
Q1 		$19K Sell
361
-75
-17% -$3.47K 0.01% 332
2013
Q4 		$17K Buy
436
+246
+129% +$9.69K 0.01% 488
2013
Q3 		$7K Buy
+190
New +$7.41K ﹤0.01% 471

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Waverly Advisors's TEVA Position: Q1 2026 in Review

Waverly Advisors increased its Teva Pharmaceuticals (TEVA) stake by 1.8% in Q1 2026, buying an estimated $6.82K and bringing the position to 11,896 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

Waverly Advisors first reported a position in TEVA in Q3 2013 and has held it in 11 quarters since. The position peaked at $365K in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Waverly Advisors held 11,896 shares of Teva Pharmaceuticals worth $358K as of Q1 2026.
  • Waverly Advisors bought 212 Teva Pharmaceuticals shares in Q1 2026, an estimated $6.82K.
  • Teva Pharmaceuticals made up ﹤0.01% of Waverly Advisors's portfolio in Q1 2026, its #1224 holding.
  • Waverly Advisors first reported a position in Teva Pharmaceuticals in Q3 2013 and has held it in 11 quarters since.
  • Waverly Advisors's Teva Pharmaceuticals position peaked at $365K in Q4 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.